GENEVA — Malaria vaccine manufacturers GSK and Bharat Biotech have announced a significant price cut. They aim to offer the RTS,S vaccine for less than $5 per dose. This move arrives as the Gavi vaccination initiative faces funding strain, with reduced UK contributions and no US pledge.
The companies state the lower price reflects their commitment to Gavi. This results from manufacturing process improvements and expanded production capacity. They are operating with minimal profit margins on the vaccine.
Bharat Biotech will fully manage production as prices reach below $5. GSK will continue to supply the adjuvant, a key vaccine component. This partnership ensures sustained supply for global needs.
Malaria Vaccine Price Reduction
This malaria vaccine price reduction supports wider access for children. It addresses critical funding gaps faced by global health programs. The reduced cost makes the vaccine more attainable for many nations.
Rationale Behind the Malaria Vaccine Price Reduction
Dr. Krishna Ella, Executive Chairman of Bharat Biotech, called the effort “a promise.” He highlighted collaboration with GSK, Gavi, and WHO to meet children’s urgent malaria protection needs. This cooperation aims to close the gap between supply and demand.
Clinical trials show the RTS,S vaccine cuts severe malaria hospitalizations by 30%. Experts acknowledge its utility, though some note it is less effective than older methods like bed nets. Professor Nick White believes it offers reasonable short-term protection and is a useful addition to other health measures.
Gavi plans to fund the RTS,S vaccine in 12 African countries soon. The malaria vaccine price reduction is a welcome development for increasing availability. This step helps make the lifesaving tool more accessible to those who need it most.
By Abiodun Labi
